Cargando…

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

OBJECTIVES: Clinical trials of tumour necrosis factor antagonists have raised questions about the potential risk of certain serious adverse events (SAE). To assess the safety of adalimumab in rheumatoid arthritis (RA) over time and across five other immune-mediated inflammatory diseases and to compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, G R, Mease, P, Dijkmans, B A C, Gordon, K, Lovell, D, Panaccione, R, Perez, J, Pangan, A L
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2009
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770105/ https://www.ncbi.nlm.nih.gov/pubmed/19147611 http://dx.doi.org/10.1136/ard.2008.102103

Ejemplares similares

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
por: van der Heijde, D, et al.
Publicado: (2008)

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
por: Burmester, Gerd R., et al.
Publicado: (2019)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis
por: Burgos-Vargas, R, et al.
Publicado: (2013)

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
por: van Kuijk, A W R, et al.
Publicado: (2008)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Six-year mortality in a street-recruited cohort of homeless youth in San Francisco, California
por: Auerswald, Colette L., et al.
Publicado: (2016)

Liver cancer mortality over six decades in an epidemic area: what we have learned
por: Chen, Jian-Guo, et al.
Publicado: (2021)

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
por: Van den Bosch, Filip, et al.
Publicado: (2018)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
por: Smolen, J, et al.
Publicado: (2008)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

A psychometric analysis of outcome measures in peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2016)

Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases
por: Hu, Kaimin, et al.
Publicado: (2019)

Somali women and their pregnancy outcomes postmigration: data from six receiving countries
por: Small, R, et al.
Publicado: (2008)

Disparities in pre-eclampsia and eclampsia among immigrant women giving birth in six industrialised countries
por: Urquia, ML, et al.
Publicado: (2014)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
por: Rudwaleit, M, et al.
Publicado: (2008)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
por: Camidge, D R, et al.
Publicado: (2006)

Does living at moderate altitudes in Austria affect mortality rates of various causes? An ecological study
por: Burtscher, Johannes, et al.
Publicado: (2021)

Unintentional injuries in children in the south of Iran, 2004–2019: a trend analysis of mortality rates
por: Azarbakhsh, Habibollah, et al.
Publicado: (2023)

Inpatient hospitalisation and mortality rate trends from 2004 to 2014 in the USA: a propensity score-matched case–control study of hyperkalaemia
por: Tecson, Kristen Michelle, et al.
Publicado: (2022)

Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040
por: Wéber, András, et al.
Publicado: (2023)

From the index case to global spread: the global mobility based modelling of the COVID-19 pandemic implies higher infection rate and lower detection ratio than current estimates
por: Siwiak, Marian, et al.
Publicado: (2020)

Estimation of perinatal mortality rate for institutional births in Rajasthan state, India, using capture–recapture technique
por: Mony, Prem K, et al.
Publicado: (2015)

Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019
por: Wang, Rui, et al.
Publicado: (2023)

Mortality in women given diethylstilbestrol during pregnancy
por: Titus-Ernstoff, L, et al.
Publicado: (2006)

Vitamin K and childhood cancer: analysis of individual patient data from six case–control studies
por: Roman, E, et al.
Publicado: (2002)

Risk of breast cancer among users of aspirin and other anti-inflammatory drugs
por: García Rodríguez, L A, et al.
Publicado: (2004)

Six simple questions to detect malnutrition or malnutrition risk in elderly women
por: Gutiérrez-Gómez, Tranquilina, et al.
Publicado: (2015)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
por: ten Hagen, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ddvj191hu4ui20ur2u202ckk1n